key: cord-0713724-6r23yk5v authors: Islam, Amin; Rafiq, Shafqat; Karim, Sabina; Laher, Ismail; Rashid, Harunor title: Convalescent plasma therapy in the treatment of COVID-19: practical considerations: Correspondence date: 2020-06-02 journal: Int J Surg DOI: 10.1016/j.ijsu.2020.05.079 sha: 22b9b6715eb3b36c7ec782a2ce739680e8848d05 doc_id: 713724 cord_uid: 6r23yk5v nan All authors contributed equally in the preparation of the manuscript, seen and approved the final version. Dr Amin Islam. No conflicts of interest to declare. currently no cure for it. Convalescent plasma therapy (CPT) was used to treat a limited number of COVID-19 cases in China and South Korea, where five observational studies (involving 27 patients) reported recovery from illnesses and reduction in viral load (Table 1 ) [1] [2] [3] [4] [5] , although this was not confirmed in another study involving six patients [6] . The development of immunity to a pathogen involves an innate response followed by an adaptive response, where the body makes specific antibodies to clear offending pathogens. Patients recovering from infections have variable antibody levsls which can be used to treat other critically ill patients. Fully recovered donors can donate plasma by plasmapheresis, but where this is unavailable, whole blood is collected and plasma separated for transfusion to the patient maintaining optimum conditions of storage, defrosting and administration techniques (including 24 hours post thaw expiry rule) for fresh frozen plasma . Whole blood should be stored between 2°C and 6°C for a duration that depends on the anticoagulant and preservative used. Liquid plasma can be stored between 1°C and 6°C for up to 40 days, and plasma frozen at -18°C or lower (stored within 24 hours after blood collection) can be stored for up to 12 months. Inactivation of plasma pathogens should be confirmed to minimise the risks of transfusiontransmitted infectious diseases and to rule out the possible risk of super-infection with SARS- It is recommended that SARS-CoV-2 neutralising antibody (NAbs) titres should be greater than 1:320, but lower thresholds could also be effective. Plasma is released for transfusion without antibody testing in emergency situations, and archived samples tested later to confirm adequate levels of Nabs. Most people with high levels of antibody can donate plasma every two weeks as long as the titres remain adequate. A sample of donor plasma stored should be saved at -20°C or lower for retrospective testing of total and anti-SARS-CoV-2 NAbs titres and other investigations dictated by the patient's status. Blood/serum/plasma samples of the recipient (both prior to, and after transfusion) should be collected for haemovigilance. It is important to ensure ABO compatibility of plasma between donors and recipients to avoid Rhesus D (RhD) sensitisation when whole blood is transfused. Transfusion of plasma from at least two donors may be therapeutically beneficial to achieve more effective immune protection from delivery of diverse antibodies. Patients can receive an initial transfusion of 200 mL, followed by one or two additional transfusions of 200 mL according to disease severity and tolerance to the infusions. Although CPT is likely to have potential benefits and low risks, the complications of CPT (e.g., allergic transfusion reactions, transfusion-associated circulatory overload (TACO), and transfusion-related acute lung injury (TRALI) are not likely to be different from satndard transfusions particularly in developed nations . While the risk of TRALI is generally <1/ 5,000 units transfused, it is of particular concern in severe COVID-19 infections given the potential priming of the pulmonary endothelium (which can be mitigated by donor screening). Of note, risk factors for TACO (e.g., cardiorespiratory disease, advanced age, renal Finally, it is unclear if convalescent plasma can blunt the development of a natural immune response, especially when used prophylactically. There are multiple clinical trials taking place in several countries including in the UK (e.g., REMAP-CAP and RECOVERY Trials). People who have recovered from COVID-19 for more than 28 days, with no transfusion transmitted diseses and who are not pregnant are eligible to participate. Recipients will be followed throughout their hospitalisation and a month after discharge. While we await trial results, we recommend that CPT be considered for patients severely ill with COVID-19 upon hospitalisation. No ethical approval required. Not Commissioned, internally reviewed. The following additional information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories, then this should be stated. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection Effectiveness of convalescent plasma therapy in severe COVID-19 patients Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Treatment with convalescent plasma for COVID-19 Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients review, SK prepared the table, IL revised all versions of the manuscript. All authors contributed equally in the preparation of the manuscript, seen and approved the final version. The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. Please note that providing a guarantor is compulsory.Dr Amin Islam is the guarantor of the manuscript.